ZYBERNO
Stock Report
Updated Jun 5, 2026

RAPT Therapeutics, Inc. (RAPT)

Healthcare • NASDAQ

$58.02

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
18.0/100
POOR BUSINESS
RAPT Therapeutics, Inc. (RAPT) scores 18/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-61.8%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.06x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-1,001.0%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

RAPT Therapeutics, Inc. (RAPT) stock report — Zyberno Score 18/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, RAPT generated -$108.69M in Owner Earnings. Capital was deployed as follows: $60.00K invested in capital expenditures. Reinvestment rate: 1.3%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:58.02
Market Cap:$1.56B

Valuation Multiples (2)

P/B Ratio:10.29x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$1.41B
B. Profitability Assessment

Return Metrics (5)

ROA:-54.7%
Reinvestment Rate:1.3%
Fundamental Growth Rate (g):-12.8%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$4.48
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-38.1%
Latest Earnings Filed:2025-11-06
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:12.04x
Quick Ratio:12.04x
Cash Ratio:11.76x

Leverage Analysis (3)

Debt To Equity Ttm:0.06x
Debt-to-Equity Ratio:0.06x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:147,670,000.00
Cash And Cash Equivalents:157,300,000.00
Long Term Debt:$387.00K
Net Debt:-$154.70M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$112.64M

Bottom Line Performance (3)

-$105.64M
Income Before Tax:-$69.20M
Ebitda Ttm:-111,695,000.00

Operating Expenses (5)

Operating Expenses:112,636,000.00
R And D Expense:82,872,000.00
Sga Expense:29,764,000.00
Income Tax Expense:$0.00
Interest Expense:0.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$165.74M
Current Assets:$161.05M
Ppe Net:11,146,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:13,762,000.00
Current Liabilities:13,375,000.00
Long Term Debt:$387.00K
Short Term Debt:$2.21M

Equity & Capital (3)

Equity:$151.98M
Retained Earnings:-$666.94M
Common Stock:2,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:9,008,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:5,029,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$108.63M-$108.69M

Investment Activities (2)

Investing Cash Flow:-$57.06M
Capital Expenditures Ttm:60,000.00

Financing Activities (3)

Financing Cash Flow:$0.00
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:1,180,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:941,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-2.60
-$2.60
Earnings Per Share Ttm:-$3.92

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$3.09

Book Value & Capital (2)

Book Value Per Share:$5.64
Cash Per Share:5.83

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$108.69M

Damodaran Growth Analysis (2)

Reinvestment Rate:1.3%
Fundamental Growth Rate (g):-12.8%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):-9.0%
C. Company Profile & Context

Corporate Information (6)

Symbol:RAPT
Company Name:RAPT Therapeutics, Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:high
Volume Category:N/A

Share Structure (3)

Shares Outstanding:26.96M
Shares Outstanding Basic:26.96M
Shares Outstanding Diluted:26.96M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-06-05 07:49:12 UTC
Data Timestamp:2026-06-05T07:49:12.365503
Scroll to Top